IASLC WCLC 2021: Selpercatinib Has Durable Antitumor Activity in RET Fusion-Positive Advanced Non–Small Cell Lung Cancer
Treatment-emergent adverse events due to selpercatinib need a more rigorous evaluation in the next phase of the study.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.